XIST and neoplasm: Additionally, compared with the treatment with silencing XIST, co-treatment of si-XIST and oe-MYC and co-treatment of si-XIST and miR-29a inhibitor resulted in increased tumor volume and weight, up-regulated expression of MYC and Bcl-2 but down-regulated expression of BAX and Cleaved-caspase 3 (Fig. 5c, d).